Urbana, IL, United States
Urbana, IL, United States

Rockford University is a private American liberal arts college in Rockford, Illinois. It was founded in 1847 as Rockford Female Seminary and changed its name to Rockford College in 1892, and to Rockford University in 2013. The university is known as the alma mater of Nobel Peace Prize winner Jane Addams, who was a member of the class of 1881. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

News Article | May 3, 2017
Site: www.businesswire.com

MARSHALL, Minn.--(BUSINESS WIRE)--Schwan’s Company announced today that Tony Puri has been named executive vice president of SFC Global Supply Chain, Inc., a subsidiary of Schwan’s Company. In this role, Puri will be responsible for the strategic direction and performance of the company’s manufacturing facilities and distribution centers. He will also serve on the company’s executive leadership team. “Tony is a proven leader and has tremendous experience in the successful operations of manufacturing facilities throughout the world,” said Schwan’s Company CEO Dimitrios Smyrnios. “Our entire team is looking forward to working with him to deliver world-class service to our customers and increase our capacity for growth.” Puri brings more than 30 years of food-industry experience to his new role. Most recently, he served as vice president of global manufacturing for CSM Bakery Solutions, where he was responsible for the overall operations of 34 manufacturing facilities, and quality and engineering teams worldwide. Prior to CSM, he worked in leadership and general management roles with several global companies. He started his career with Ralston Purina before progressing to other leadership roles with Cadbury, Warner Lambert, Kraft and Mondelez International. He earned bachelor’s and master’s degrees in biochemical and chemical engineering from Rutgers University. He also obtained a master’s degree in business administration, marketing and finance from Rockford College in Illinois. Puri is filling a role previously held by Doug Olsem, who recently accepted a newly created position leading Schwan’s sourcing, Contract Partner Sales business, travel and real estate teams.


Negro R.,V Fazzi Hospital | Stagnaro-Green A.,Rockford College
BMJ (Online) | Year: 2014

In prospective studies, the prevalence of undiagnosed subclinical hypothyroidism in pregnant women ranges from 3% to 15%. Subclinical hypothyroidism is associated with multiple adverse outcomes in the mother and fetus, including spontaneous abortion, pre-eclampsia, gestational hypertension, gestational diabetes, preterm delivery, and decreased IQ in the offspring. Only two prospective studies have evaluated the impact of levothyroxine therapy in pregnant women with subclinical hypothyroidism, and the results were mixed. Subclinical hypothyroidism is defined as raised thyrotropin combined with a normal serum free thyroxine level. The normal range of thyrotropin varies according to geographic region and ethnic background. In the absence of local normative data, the recommended upper limit of thyrotropin in the first trimester of pregnancy is 2.5 mlU/L, and 3.0 mlU/L in the second and third trimester. The thyroid gland needs to produce 50% more thyroid hormone during pregnancy to maintain a euthyroid state. Consequently, most women on levothyroxine therapy before pregnancy require an increase in dose when pregnant to maintain euthyroidism. Ongoing prospective trials that are evaluating the impact of levothyroxine therapy on adverse outcomes in the mother and fetus in women with subclinical hypothyroidism will provide crucial data on the role of thyroid hormone replacement in pregnancy.


Negro R.,V Fazzi Hospital | Stagnaro-Green A.,Rockford College
Endocrine Practice | Year: 2014

Objective: To evaluate the peer-reviewed literature on hypothyroidism, hyperthyroidism, and thyroid autoimmunity in pregnancy.Methods: We review published studies on thyroid autoimmunity and dysfunction in pregnancy, the impact of thyroid disease on pregnancy, and discuss implications for screening.Results: Overt hyperthyroidism and hypothyroidism are responsible for adverse obstetric and neonatal events. Several studies of association suggest that either subclinical hypothyroidism or thyroid autoimmunity increase the risk of complications. One randomized controlled trial showed that pregnant women with subclinical hypothyroidism benefit from treatment in terms of obstetric and neonatal complications, whereas another study demonstrated no benefit in the intelligence quotient of babies born to women with subclinical hypothyroidism. Thyroid autoimmunity has been associated with increased rate of pregnancy loss, recurrent miscarriage, and preterm delivery.Conclusion: Current guidelines agree that overt hyperthyroidism and hypothyroidism need to be promptly treated and that as potential benefits outweigh potential harm, subclinical hypothyroidism also requires substitutive treatment. The chance that women with thyroid autoimmunity may benefit from levothyroxine treatment to improve obstetric outcome is intriguing, but adequately powered randomized controlled trials are needed. The issue of universal thyroid screening at the beginning of pregnancy is still a matter of debate, and aggressive case-finding is supported. © 2014 AACE.


Joseph S.K.,Rockford College | Joseph S.K.,U.S. National Institutes of Health | Ramaswamy K.,Rockford College
Vaccine | Year: 2013

The multivalent vaccine BmHAT, consisting of the Brugia malayi infective larval (L3) antigens heat shock protein12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and tetraspanin large extra cellular loop (TSP-LEL), was shown to be protective in rodent models from our laboratory. We hypothesize that since these antigens were identified using protective antibodies from immune endemic normal individuals, the multivalent vaccine can be augmented by natural L3 infections providing protection to the vaccinated host. This hypothesis was tested using single dose of DNA and protein or protein alone of the BmHAT vaccination in gerbils followed by live trickle L3 infection as booster dose. Vaccine-induced protection in gerbils was determined by worm establishment, micropore chamber assay and by antibody dependant cell cytotoxicity (ADCC) assay. Results were compared with the traditional prime-boost vaccination regimen. Gerbils vaccinated with BmHAT and boosted with L3 trickle infection were protected 51% (BmHAT DNA-protein) and 48% (BmHAT protein) respectively. BmHAT vaccination plus L3 trickle booster generated significant titer of antigen-specific IgG antibodies comparable to the traditional prime boost vaccination approach. BmHAT vaccination plus L3 trickle booster also generated antigen-specific cells in the spleen of vaccinated animals and these cells secreted predominantly IFN-γ and IL-4 in response to the vaccine antigens. These studies thus show that single dose of BmHAT multivalent vaccination followed by L3 trickle booster infection can confer significant protection against lymphatic filariasis. © 2013 Elsevier Ltd.


Thirugnanam S.,Rockford College | Rout N.,Harvard University | Gnanasekar M.,Rockford College
Infectious Agents and Cancer | Year: 2013

Background: The obligate intracellular protozoan parasite Toxoplasma gondii infects humans and other warm-blooded animals and establishes a chronic infection in the central nervous system after invasion. Studies showing a positive correlation between anti-Toxoplasma antibodies and incidences of brain cancer have led to the notion that Toxoplasma infections increase the risk of brain cancer. However, molecular events involved in Toxoplasma induced brain cancers are not well understood. Presentation of the hypothesis. Toxoplasma gains control of host cell functions including proliferation and apoptosis by channelizing parasite proteins into the cell cytoplasm and some of the proteins are targeted to the host nucleus. Recent studies have shown that Toxoplasma is capable of manipulating host micro RNAs (miRNAs), which play a central role in post-transcriptional regulation of gene expression. Therefore, we hypothesize that Toxoplasma promotes brain carcinogenesis by altering the host miRNAome using parasitic proteins and/or miRNAs. Testing the hypothesis. The miRNA expression profiles of brain cancer specimens obtained from patients infected with Toxoplasma could be analyzed and compared with that of normal tissues as well as brain cancer tissues from Toxoplasma uninfected individuals to identify dysregulated miRNAs in Toxoplasma-driven brain cancer cells. Identified miRNAs will be further confirmed by studying cancer related miRNA profiles of the different types of brain cells before and after Toxoplasma infection using cell lines and experimental animals. Expected outcome. The miRNAs specifically associated with brain cancers that are caused by Toxoplasma infection will be identified. Implications of the hypothesis. Toxoplasma infection may promote initiation and progression of cancer by modifying the miRNAome in brain cells. If this hypothesis is true, the outcome of this research would lead to the development of novel biomarkers and therapeutic tools against Toxoplasma driven brain cancers. © 2013 Thirugnanam et a;.


Ruden M.,Rockford College | Ruden M.,University of Illinois at Chicago | Puri N.,Rockford College
Cancer Treatment Reviews | Year: 2013

Telomeres are protective caps at the ends of human chromosomes. Telomeres shorten with each successive cell division in normal human cells whereas, in tumors, they are continuously elongated by human telomerase reverse transcriptase (hTERT). Telomerase is overexpressed in 80-95% of cancers and is present in very low levels or is almost undetectable in normal cells. Because telomerase plays a pivotal role in cancer cell growth it may serve as an ideal target for anticancer therapeutics. Inhibition of telomerase may lead to a decrease of telomere length resulting in cell senescence and apoptosis in telomerase positive tumors. Several strategies of telomerase inhibition are reviewed, including small molecule inhibitors, antisense oligonucleotides, immunotherapies and gene therapies, targeting the hTERT or the ribonucleoprotein subunit hTER. G-quadruplex stabilizers, tankyrase and HSP90 inhibitors targeting telomere and telomerase assembly, and T-oligo approach are also covered. Based on this review, the most promising current telomerase targeting therapeutics are the antisense oligonucleotide inhibitor GRN163L and immunotherapies that use dendritic cells (GRVAC1), hTERT peptide (GV1001) or cryptic peptides (Vx-001). Most of these agents have entered phase I and II clinical trials in patients with various tumors, and have shown good response rates as evidenced by a reduction in tumor cell growth, increased overall disease survival, disease stabilization in advanced staged tumors and complete/partial responses. Most therapeutics have shown to be more effective when used in combination with standard therapies, resulting in concomitant telomere shortening and tumor mass shrinkage, as well as preventing tumor relapse and resistance to single agent therapy. © 2012 Elsevier Ltd.


Stagnaro-Green A.,Rockford College
Frontiers in Endocrinology | Year: 2015

During pregnancy, the thyroid gland must produce 50% more thyroid hormone to maintain the euthyroid state. Women with decreased thyroid reserve preconception, most typically due to Hashimoto's thyroiditis, may develop hypothyroidism during pregnancy. Data over the last 20 years have reported a strong association between subclinical hypothyroidism and adverse maternal/fetal events. As a result of this association, an increasing number of women are being screened for thyroid disease either preconception or at the first prenatal visit. Consequently, an ever increasing number of women are being initiated on levothyroxine for the first time during pregnancy. At present, there are very limited guidelines related to the management of the thyroid disease in these women postpartum. Based on an understanding of the physiology of the thyroid gland during pregnancy and postpartum, and the personal clinical experience of the author, recommendations for the postpartum management of women who were started on levothyroxine during pregnancy are presented. © 2015 Stagnaro-Green.


Kaskavage J.,Rockford College | Sklansky D.,Rockford College
Pediatrics | Year: 2012

Adolescents with well-controlled cystic fibrosis, including good lung function and appropriate growth, commonly participate in competitive athletic activities. We present the case of an adolescent male with cystic fibrosis, hyponatremia, dehydration, and rhabdomyolysis after participating in football practice on a summer morning. The patient presented with severe myalgia and serum sodium of 129 mmol/L, chloride 90 mmol/L, and creatine phosphokinase 1146 U/L. Aggressive hydration with intravenous 0.9% saline resulted in clinical improvement with no renal or muscular sequelae. Health care providers need to educate patients with cystic fibrosis about maintaining adequate hydration and sodium repletion during exercise. Research is needed regarding the appropriate amount and composition of oral rehydration fluids in exercising individuals with cystic fibrosis, as the physiology encountered in these patients provides a unique challenge to maintaining electrolyte balance and stimulation of thirst. Copyright © 2012 by the American Academy of Pediatrics.


Nitiss K.C.,Rockford College | Nitiss J.L.,Rockford College
Clinical Cancer Research | Year: 2014

Anthracyclines are active clinical agents that have multiple mechanisms of cytotoxicity. Cardiotoxicity by anthracyclines limits the therapeutic potential of these agents, but mechanisms leading to cardiotoxicity remain controversial. Transgenic mice that lack mitochondrial topoisomerase I are hypersensitive to doxorubicin cardiotoxicity, providing support for cardiotoxicity arising from damage of mitochondrial DNA.


Dalstrom M.,Rockford College
Anthropology and Medicine | Year: 2013

International medical travel is a rapidly developing phenomenon that promises patients cheap and affordable medical care abroad. However, the logistics of making travel arrangements, selecting a medical provider, and evaluating quality can be a daunting task for even the most experienced traveler. At the nexus, connecting patients and providers are medical travel facilitators (MTFs), who are individuals and companies that market foreign medical care to patients. While the services that MTFs offer vary, they primarily focus on making foreign medical care more accessible to patients through commodifying the medical experience and providing logistical support. Although they are an important part of international medical travel they are often overlooked, especially along the US/Mexico border. This paper contributes to the discussion on medical travel by focusing on MTFs and the methods they employ through (1) discussing the characteristics and logistical challenges of medical travel; (2) identifying the different types of medical travel facilitators; and (3) addressing how MTFs remake patients into consumers. Findings suggest that while MTFs operate on a variety of different scales, and market their services differently, they all emphasize the consumer experience through advertising quality assurances and logistical support. © 2013 Taylor & Francis Group, LLC.

Loading Rockford College collaborators
Loading Rockford College collaborators